A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2057-3804
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma ; volume:6 ; number:1 ; day:13 ; month:10 ; year:2020 ; pages:1-4 ; date:12.2020
Cardio-Oncology ; 6, Heft 1 (13.10.2020), 1-4, 12.2020
- Creator
-
Ko Ko, Nway Le
Minaskeian, Nareg
El Masry, Hicham Z.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40959-020-00077-5
- URN
-
urn:nbn:de:101:1-2020112819221896988389
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ko Ko, Nway Le
- Minaskeian, Nareg
- El Masry, Hicham Z.
- SpringerLink (Online service)
Other Objects (12)
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
Personalized Medicine in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma: An institutional analysis
Case of Gastric Diffuse Large B-Cell Lymphoma
Molecular Classification of Diffuse Large B-Cell Lymphoma
METTL3-mediated m6A methylation of C1qA regulates the Rituximab resistance of diffuse large B-cell lymphoma cells
Targeting HDACs for diffuse large B-cell lymphoma therapy
Concurrent Pilomatrix Carcinoma and Diffuse Large B-Cell Lymphoma
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
Personalized Medicine in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma: An institutional analysis
Case of Gastric Diffuse Large B-Cell Lymphoma
Molecular Classification of Diffuse Large B-Cell Lymphoma
METTL3-mediated m6A methylation of C1qA regulates the Rituximab resistance of diffuse large B-cell lymphoma cells
Targeting HDACs for diffuse large B-cell lymphoma therapy
Concurrent Pilomatrix Carcinoma and Diffuse Large B-Cell Lymphoma
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
Personalized Medicine in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma: An institutional analysis
Case of Gastric Diffuse Large B-Cell Lymphoma
Molecular Classification of Diffuse Large B-Cell Lymphoma
METTL3-mediated m6A methylation of C1qA regulates the Rituximab resistance of diffuse large B-cell lymphoma cells
Targeting HDACs for diffuse large B-cell lymphoma therapy